Mylan Inc. closed an offering of $750,000,000 4.550% senior notes due 2028 and $750,000,000 5.200% senior notes due 2048. The notes are guaranteed by Mylan N.V., which is Mylan Inc.’s parent company. The offering was conducted pursuant to Rule 144A and Regulation S under the Securities Act.
Mylan is a leading global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics, branded generics, brand name and over-the-counter products in a variety of dosage forms and therapeutic categories. Mylan offers one of the industry’s broadest product portfolios, including more than 7,500 marketed products around the world, to customers in more than 165 countries and territories.
S&C acted as counsel for the initial purchasers.
The S&C team was led by Robert Downes, along with Brian Farber, Jonathan Gordon and Steven Mermelstein. Jeffrey Hochberg and Saul Brander advised on tax matters, and Saul Brander and Precious Nwankwo advised on ERISA matters.